A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,419,792 shares of KALV stock, worth $12.7 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,419,792
Previous 2,050,000 30.74%
Holding current value
$12.7 Million
Previous $24.1 Million 31.92%
% of portfolio
0.03%
Previous 0.05%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$9.46 - $15.39 $5.96 Million - $9.7 Million
-630,208 Reduced 30.74%
1,419,792 $16.4 Million
Q2 2024

Aug 14, 2024

SELL
$10.35 - $12.49 $5.43 Million - $6.56 Million
-525,000 Reduced 20.39%
2,050,000 $24.1 Million
Q1 2024

May 15, 2024

BUY
$11.07 - $16.04 $20.7 Million - $30 Million
1,870,000 Added 265.25%
2,575,000 $30.5 Million
Q4 2023

Feb 14, 2024

SELL
$7.58 - $12.25 $2.67 Million - $4.31 Million
-351,691 Reduced 33.28%
705,000 $8.64 Million
Q3 2023

Nov 14, 2023

SELL
$8.95 - $11.35 $426,449 - $540,804
-47,648 Reduced 4.31%
1,056,691 $10.2 Million
Q2 2023

Aug 14, 2023

BUY
$7.73 - $10.57 $309,200 - $422,800
40,000 Added 3.76%
1,104,339 $9.94 Million
Q4 2022

Feb 14, 2023

SELL
$4.2 - $14.24 $63,000 - $213,600
-15,000 Reduced 1.39%
1,064,339 $7.19 Million
Q3 2022

Nov 14, 2022

SELL
$9.85 - $16.83 $246,250 - $420,749
-25,000 Reduced 2.26%
1,079,339 $15.7 Million
Q2 2022

Aug 15, 2022

BUY
$8.16 - $15.1 $1.63 Million - $3.02 Million
200,000 Added 22.12%
1,104,339 $10.9 Million
Q1 2022

May 16, 2022

BUY
$11.2 - $16.97 $224,000 - $339,400
20,000 Added 2.26%
904,339 $13.3 Million
Q3 2021

Nov 15, 2021

SELL
$17.11 - $24.49 $11,309 - $16,187
-661 Reduced 0.07%
884,339 $15.4 Million
Q2 2021

Aug 16, 2021

BUY
$23.12 - $29.91 $1.85 Million - $2.39 Million
80,000 Added 9.94%
885,000 $21.2 Million
Q1 2021

May 17, 2021

BUY
$14.69 - $42.57 $7.42 Million - $21.5 Million
505,000 Added 168.33%
805,000 $20.7 Million
Q4 2020

Feb 16, 2021

SELL
$12.88 - $19.47 $1.29 Million - $1.95 Million
-100,000 Reduced 25.0%
300,000 $5.7 Million
Q1 2020

May 15, 2020

SELL
$5.8 - $18.56 $580,000 - $1.86 Million
-100,000 Reduced 20.0%
400,000 $3.06 Million
Q4 2019

Feb 14, 2020

SELL
$10.31 - $17.81 $2.06 Million - $3.56 Million
-200,000 Reduced 28.57%
500,000 $8.91 Million
Q2 2019

Aug 14, 2019

BUY
$18.44 - $30.89 $645,400 - $1.08 Million
35,000 Added 5.26%
700,000 $15.5 Million
Q1 2019

May 15, 2019

BUY
$16.51 - $31.1 $1.07 Million - $2.02 Million
65,000 Added 10.83%
665,000 $19 Million
Q4 2018

Feb 14, 2019

BUY
$16.21 - $24.06 $4.78 Million - $7.09 Million
294,813 Added 96.6%
600,000 $11.9 Million
Q3 2018

Nov 14, 2018

BUY
$8.0 - $22.11 $2.44 Million - $6.75 Million
305,187 New
305,187 $6.75 Million

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $220M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.